Who are Ziltivekimab C's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): TCI507, Recaticimab and Statin, Placebo (ziltivekimab), AV024.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ziltivekimab-c.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Ziltivekimab C — Competitive Intelligence Brief

Ziltivekimab C (Ziltivekimab C) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: IL-6 inhibitor monoclonal antibody. Area: Cardiovascular.

phase 3 IL-6 inhibitor monoclonal antibody Interleukin-6 (IL-6) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Ziltivekimab C (Ziltivekimab C) — Novo Nordisk A/S. Ziltivekimab is a monoclonal antibody that inhibits interleukin-6 (IL-6) signaling to reduce inflammation and cardiovascular risk.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Ziltivekimab C TARGET	Ziltivekimab C	Novo Nordisk A/S	phase 3	IL-6 inhibitor monoclonal antibody	Interleukin-6 (IL-6)
TCI507	TCI507	National Taiwan University Hospital	marketed	IL-6 inhibitor monoclonal antibody	IL-6 or IL-6 receptor
Recaticimab and Statin	Recaticimab and Statin	Peking Union Medical College Hospital	marketed	IL-6 inhibitor monoclonal antibody + HMG-CoA reductase inhibitor	IL-6 receptor / HMG-CoA reductase
Placebo (ziltivekimab)	Placebo (ziltivekimab)	Novo Nordisk A/S	phase 3	IL-6 inhibitor monoclonal antibody	IL-6
AV024	AV024	MedImmune LLC	phase 3	IL-6 inhibitor monoclonal antibody	IL-6 or IL-6 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (IL-6 inhibitor monoclonal antibody class)

Novo Nordisk A/S · 2 drugs in this class
MedImmune LLC · 1 drug in this class
National Taiwan University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ziltivekimab C — Competitive Intelligence Brief. https://druglandscape.com/ci/ziltivekimab-c. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab